Julian Grundler
About Julian Grundler
Julian Grundler is a Graduate Researcher at Yale University, specializing in lipid nanoparticles for mRNA delivery. He has contributed to several significant publications and has a background in research from institutions such as Rollins College and MIT.
Current Role at Yale University
Julian Grundler currently serves as a Graduate Researcher at Yale University, a position he has held since 2018. In this role, he focuses on the development of advanced lipid nanoparticles for mRNA delivery. His work includes the creation of a novel PEG-bottlebrush lipid aimed at enhancing the performance of these nanoparticles. Additionally, he is responsible for lab safety as the lead lab safety officer, overseeing safety trainings, chemical safety protocols, waste disposal, and communication with Environmental Health and Safety (EHS).
Education and Expertise
Julian Grundler achieved his PhD from Yale University, where he studied from 2018 to 2023. Prior to this, he earned a Bachelor's degree in Chemistry, graduating Summa Cum Laude from Rollins College between 2014 and 2018. His educational background provides a strong foundation in chemical research, particularly in the field of drug delivery systems and nanoparticle technology.
Research Contributions and Publications
Julian Grundler has contributed to several significant research projects and publications. He co-authored a manuscript submitted to Science Translational Medicine, focusing on the characterization of PEG surface density in mRNA-loaded polyplex nanoparticles for an inhalable mucosal COVID vaccine. He has also published papers in Nature Communications and ACS Nano, addressing topics such as the orientation of antibodies on nanoparticles and methods to control the surface properties of PEGylated nanoparticles, respectively.
Previous Research Experience
Before his current role, Julian Grundler gained research experience as an Undergraduate Researcher at Rollins College from 2016 to 2018 and at the Massachusetts Institute of Technology for two months in 2017. He also worked as a Research Analyst at TBF Global Asset Management GmbH in Germany from 2013 to 2014. His diverse research background includes collaborations with the Gates Foundation on developing a contraceptive polymer-drug implant.